The ultimate goal of glaucoma management is the preservation of patients' visual function and These aspects are summarized and critically appraised in this article.
INTRODUCTION
The World Health Organization (WHO) defines health as ''A state of complete physical, mental, and social well-being not merely the absence of a disease…''. It follows that the measurement of health and the effects of health care must include not only an indication of changes in the frequency and severity of diseases but also an estimation of well-being. This can be Visual impairment due to ophthalmological diseases has a negative impact on physical and mental health and is a global concern. In the USA, visual disability ranks among the top ten disabilities [3] . Visually impaired people are at higher risk than the healthy population for accidents, social withdrawal, and depression [4] [5] [6] [7] . With population aging, the number of people with visual impairment and blindness is rapidly growing, as many eye diseases are more prevalent among the elderly. Cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy are the most common causes of visual impairment [8] . In 2011, 2.71 million people in the USA had primary open-angle glaucoma (POAG), but this number is expected to reach 7.32 million by 2050 [9] . Several studies have examined the relationships between different eye diseases and QoL [10] [11] [12] [13] [14] . Despite substantial differences in methodological approach, these all concluded that visual impairment significantly affects QoL. This review examines the body of published literature on QoL in patients with POAG.
METHODS
The MEDLINE database was used for the literature search of this review. Although every effort was made to use references as recent as possible, articles irrespective of the year of publication were used if deemed appropriate.
The keywords searched included glaucoma, ocular hypertension, quality of life, health-related quality of life, vision-related were drafted on the basis of statements from patients and health professionals in a wide variety of cultures and diseases, in 15 collaborating centers around the world. Field centers were selected to cover differences in levels of industrialization, available health services, and other markers relevant to the measurement of QoL (e.g., role of the family, perception of time, perception of self, dominant religion) [15] . This structure means the results of WHOQOL questionnaires are comparable among populations in different socioeconomic settings [16] . WHOQOL-100 and WHOQOL-BREF have been translated into more than 20 languages ( This five-digit number is then elaborated using a unified scoring algorithm based on time trade-off data from several European studies [23] [24] [25] . The EQ-VAS cards measure self-reported general health status, using a vertical thermometer-analogue scale, where the endpoints are labeled ''best imaginable health state'' and ''worst imaginable health state'' (Fig. 1) . Equation 5D has been used in more than 3000 publications investigating QoL in a very wide range of diseases. Its widespread use is due to its design, suitable for self-completion (e.g., in postal surveys), but also useful in clinics and face-to-face interviews.
QUALITY OF LIFE IN OCULAR HYPERTENSION AND GLAUCOMA
A revised version of the WHOQOL-BREF questionnaire was used to assess the social impact of eye diseases in a developing population in Andhra Pradesh, southern India [13] . The authors calculated a total score for each of the questions and expressed this as a percentage of the total possible score, from 0 to 100, with higher scores indicating better results. with POAG and OHT, divided into five groups according to their disease severity [33] . Results were expressed in terms of utility score: utilities are preferences that patients or the general population have for certain health states, and the expressed scale is anchored between 1 (full health) and 0 (death). The mean EQ5D utility score in glaucoma patients was 0.8, which is close to the average for the Swedish population, where the study was run. No difference was found in utility scores for the first four severity stages of the disease, but the scores for stage 5 patients in at least one eye were significantly worse (p\0.05, Fig. 2 ). Total visual acuity, visual acuity in the better eye, and comorbidity significantly affected utility scores (p\0.05). Interestingly, QoL seems to be However, scores were low in the pain scale. These results can be explained by the fact that 11% of the enrolled patients had angle-closure glaucoma, a typically painful condition. There was also the stinging sensation of eye drops (89% of patients were using topical medications) or the pain caused by dysesthesic conjunctival blebs in some patients following trabeculectomy (43% had previous surgery for glaucoma). As expected, the EQ5D summed index score was influenced by years since diagnosis (p\0.05), VF loss (p\0.01), and visual acuity (p\0.01).
PATIENT-REPORTED OUTCOMES IN GLAUCOMA
The US Food and Drug Administration (FDA) recently recommended the use of patient-reported outcomes (PROs) as an umbrella term covering a broad range of health data reported by the patient [35, 36] . Some objective measurements used in clinical trials to describe a disease or its severity may fall short in capturing the impact of the disease on patients' daily life. For example, visual acuity and VF damage are useful to classify glaucoma stage, but they do not describe the effect on patient daily activities, such as driving, walking, or reading. The patient's point of view is important to completely understand how glaucoma and its treatment affect QoL, as some experience can only be interpreted first hand.
According to a systematic review, available
PROs in glaucoma literature can be classified into three major categories [35] : PROs addressing functional status related to vision, PROs addressing overall QoL, and PROs assessing other factors related to disease and treatment (i.e., symptoms, side effects, adherence, satisfaction, self-efficacy) ( Table 2 ).
The first category of PROs (i.e., those addressing functional status related to vision) refers to a set of questionnaires that investigate a patient's ability to undertake daily activities, fulfill life roles, and perform actions designed to maintain health and well-being [37] . All the questionnaires describe activities that need visual function and the patient is asked to rate these activities as difficult or problematic. In this category, a questionnaire was developed to measure patients' abilities to find their way, walk, and travel safely and independently (Independent Mobility Questionnaire, IMQ) [38] . Independent mobility perceived by glaucoma patients was associated with mean deviation (MD) in the better eye (p\0.01) and visual acuity in the better eye, the fellow eye, and in both eyes (p = 0.05) [39] . In the same category of PROs, the Glaucoma Symptom Identifier (GSI) was designed to assess multiple possible glaucoma symptoms and their impact on QoL in clinical practice [40] .
PROs assessing overall QoL include questionnaires that investigate the impact of eye diseases on QoL, as perceived by the patient. shown to be internally consistent [43, 44] , reproducible [43] , and responsive in glaucoma patients [44] . NEI-VFQs were used in randomized clinical trials, such as the Early Manifest Glaucoma Trial (EMGT) [45] and The
Tube versus Trabeculectomy Study [46] . Beside general vision-specific instruments, PROs assessing overall QoL include several glaucoma-specific tests, such as the Glaucoma Quality of Life (Glau-QoL) questionnaire [47] , the Glaucoma Health Perception Index [48, 49] , and the Glaucoma Utility Index [50] . Almost all these questionnaires include patients' input for item generation. They have good developmental characteristics, with strong evidence of validity [47] .
The third category of PROs includes questionnaires developed to assess either topical treatment or disease-related factors that can influence QoL. The Treatment Satisfaction Survey-Intraocular Pressure (TSS-IOP) is designed to evaluate patient satisfaction with various aspects of topical medications employed in glaucoma. The methods used to select and organize items were adequate [51] . Although TSS-IOP is the instrument of choice for 
QUALITY OF LIFE IN GLAUCOMA PATIENTS: LOSS OF VISUAL FUNCTION
Early detection of glaucoma is one of the objectives stressed by glaucoma societies to preserve visual function and patients' QoL [54, 55] . Patients with early glaucoma often remain undiagnosed until it progresses to advanced stages, when central vision is affected. Several studies have reported visual acuity loss as one of the causes associated with lower HR-QoL in POAG patients [33, 56, 57] . In the EMGT, the Swedish version of the NEI-VFQ-25 was self-administered to patients 3 and 6 years after randomization [44] . At the 3-year administration, the mean composite score (88.8) and mean subscale scores (98.0-58.3) were generally high and there were no differences between the treatment and observation groups. Although the patients showed good results in terms of QoL, NEI-VFQ scores were correlated with low visual acuity in the better eye, worse perimetric MD, and nuclear lens opacities; no correlation was found with age, sex, IOP, cardiovascular disease, or systemic hypertension. Larger drops in composite scores between the 3-and 6-year NEI-VFQ were associated with greater loss in visual acuity (p\0.05), but treatment (assigned at randomization or later in the study) had no effect on QoL. These results suggest that absence or delay of treatment does not influence vision-targeted QoL in early glaucoma patients up to 6 years from initial diagnosis.
A recent report from EMGT, after 20 years of follow-up, showed that many patients with VF loss of less than 50% (e.g., VF index 50% or MD -18 dB) in the better eye rated their vision-related QoL at a level similar to that reported by patients with no VF loss in the better eye [58] . These results support the arbitrary, but widely used, limit of a better-eye VF loss of less than 50% as an important VF MD in the best eye was used in another study to classify POAG patients into three stages (early, moderate, and advanced) [60] . that glaucoma patients with severe VF loss had lower QoL scores than patients with no or initial VF loss. Correlation coefficients from the better-seeing eye were significant for 6 of the 12 NEI-VFQ subscales and the NEI-VFQ composite score. Glaucoma patients had greatest difficulties driving, especially in more advanced stages of the disease. A unique feature of this study was the ability to measure self-reported QoL before the participants were diagnosed with glaucoma and therefore before they were aware of the disease. At enrollment 75% of patients affected with glaucoma were unaware of it. Interestingly, however, the association between QoL scores and VF loss persisted even after controlling for knowledge of glaucoma or when analysis was restricted to LALES patients unaware of the disease.
An objective estimation of vision-specific ability to perform activities of daily living and its correlation to clinical tests (i.e., visual acuity, visual field test, contrast sensibility, and stereopsis) was attempted in a group of glaucoma patients by Richman et al. [65] . Analyzer, and an integrated VF was calculated using the best sensitivity method [73] . 
MENTAL HEALTH STATUS AND QUALITY OF LIFE IN GLAUCOMA
Many studies have investigated the relationship between glaucoma, anxiety, and depression [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] . Although there is no actual evidence on this topic, a higher prevalence of psychological disorders in glaucoma patients can be reasonably assumed. As a result of its asymptomatic, chronic nature and potential outcome of blindness, glaucoma often imposes a psychological burden [79, 87] . Limitation of life spaces due to a variety of factors, such as driving limitations [88, 89] , fear of falling [90, 91] , and worse balance [82] , also contribute to the relationship between glaucoma and depression.
The prevalence of anxiety and depression in patients with POAG was evaluated in a case-control study [80] using the Hospital Anxiety and Depression Scale (HADS) questionnaire. The prevalence of patients with anxiety (13.0%) and depression (10.9%) was significantly higher than in the control group (7.0% and 5.2% respectively, p\0.05). When glaucoma was evaluated as a potential risk factor for anxiety and depression, a negative correlation was found between age and the HADS-Anxiety subscore, after adjusting for demographic and clinical variables (p\0.01) [81] . Interestingly, younger glaucoma patients tended to be more anxious compared to older ones, as demonstrated in studies on other chronic diseases [92, 93] . As expected, older age and decreasing MD, determined by CIGTS QoL questionnaires included an assessment of fear of blindness (FOB). As these questionnaires were administered by trained telephone interviewers every 6 months, changes in FOB were assessed continuously during the 5-year follow-up [87] . At baseline, after being told about glaucoma diagnosis but before randomization, 34% of patients reported either a moderate amount or a lot of worry about blindness (Fig. 3) . This decreased to 17% by 6 months and to 11% over a 5-year period. Almost half the patients remained at least a little worried 5 years after the diagnosis of glaucoma. In multivariate analysis, younger age, white ethnicity, low-grade education, and lower income were significantly associated with increased FOB (p = 0.006). The decrease in FOB over time was probably due to the reassurance associated with receiving treatment, regular clinical follow-up, adaptation to the diagnosis, or a combination thereof.
QUALITY OF LIFE: GLAUCOMA THERAPIES
Glaucoma treatment may influence patients' QoL in several ways. Topical and systemic side effects, difficulties in administering medications, and complexity of medication regimens are all factors that can reduce patients' satisfaction with their therapy [94] . Patients satisfied with therapy are more likely to adhere to it [95] , to take an active role in their own care [96] , and to continue using medical care services [97] .
Tsai et al., using patient interviews, created a taxonomy of reasons for poor adherence in a group of patients with glaucoma [98] .
Situational/environmental tasks explained 80% of poor compliance with therapy. The need to take drops always at the same time and the inability to carry medication bottles when away from home may be decisive factors. Routines are part of life, and changes in routine often mean a change in QoL, especially for older patients.
Similarly, side effects of eye drops, such as hyperemia, burning, stinging, foreign body sensation, and blurred vision, can influence social and environmental aspects of life besides making the patient dissatisfied with therapy. Jampel et al. administered a willingness to pay questionnaire to a group of 230 patients with glaucoma or suspected glaucoma, asking them how much they would be willing to pay for certain characteristics in eye drops [99] .
Patients were willing to pay more for eye drops that did not cause blurred vision (85%), drowsiness (83%), stinging or tearing (72%), or Other studies indicated that problems with eye drop use and complex regimens may play a role in poor compliance [101, 102] . Claxton et al. performed a systematic review of the medical literature, highlighting that fewer doses per day significantly correlated with better compliance [103] . A study of add-on therapy also suggested that patients prescribed a second ocular hypotensive medication refilled their first prescribed medication less regularly [104] . Difficulties with medication use in older patients affected with glaucoma may have several causes [105] . Medication bottles are often an obstacle to treatment because of difficulties with topical application. Moreover, many older adults with glaucoma have considerable comorbidity, such as arthritis, which impairs their ability to depress the applicators of eye drops.
QUALITY OF LIFE: OCULAR SURFACE DISEASE
Ocular surface disease (OSD) is characterized by an inadequate quantity of tears, an unstable tear film secondary to poor quality of tears, ocular surface breakdown, and/or symptoms such as irritation, burning, foreign body sensation, dryness, photophobia, fatigue, and fluctuating visual acuity [106] . OSD has an estimated prevalence of 15% among individuals older than 65 years [107] and this rises to 59% in patients with glaucoma [106] . The higher prevalence among glaucoma patients is probably due to the fact that OSD and glaucoma both have an age-dependent prevalence; furthermore, the antiglaucoma eye drops and the preservative agents (especially benzalkonium chloride, BAK) may cause inflammation [108, 109] , as well as other anterior segment ocular diseases (allergy, blepharitis, dry eye) [110] .
Skalicky et al. evaluated the impact of OSD on
QoL in 101 glaucoma patients and 23 controls [111] . All completed a glaucoma-specific QoL questionnaire (GQL-15) and an Ocular Surface Disease Index questionnaire (OSDI). OSDI is a 12-item questionnaire designed to provide a rapid assessment of OSD related to chronic dry eye, its severity, and its impact on the patient's ability to function [112] . OSDI scores correlated well with glaucoma severity in patients younger than 60 years and in the 70-79 years subgroup.
Exposure to more than three BAK-preserved drops daily was independently predictive of OSD in multivariate analysis (p = 0.018), underlining the causal role of preservatives in OSD.
Another study examined the relationship between OSD and QoL in glaucoma and OHT patients treated with BAK-preserved eye drops [113] . Patients were asked to complete the NEI-VFQ25 and Glaucoma Symptom Scale The use of BAK-preserved medications has been associated with the development of OSD [114, 115] . Few studies have examined the effects of preservative-free medications on QoL. Some looked at OSD signs (BUT, fluorescein staining, hyperemia) after changing from a preserved antiglaucoma drug to a preservative-free formulation [116] [117] [118] [119] [120] . However, as anterior segment signs are barely correlated with the severity of OSD [121, 122] , no real conclusions can be drawn on this topic.
QUALITY OF LIFE IN MEDICALLY VS. SURGICALLY TREATED GLAUCOMA PATIENTS
The CIGTS [123] was the only study identified by a Cochrane systematic review that examined QoL in medically or surgically treated glaucoma patients [124] . For this reason no firm conclusions can be drawn on this topic.
After the first 5 years of CIGTS follow-up, the QoL impact reported by the two treatment groups was not different, except that patients who underwent surgery treatment complained more frequently of local eye symptoms (something in the eye, eye pain, red eye, excessive tearing, etc.) [123] . This was not unexpected, given the presence of a filtering conjunctival bleb in the surgical group. The effect of surgery on eye symptoms was initially larger, but the magnitude of this effect decreased over time. A trend towards a reduction of symptom frequency and symptom bothersomeness was noted during the follow-up in both the surgical and medical groups. This could be related to a combination of coping, psychological adjustment and accommodation to the glaucoma diagnosis, or to the actual decrease or cessation of the particular problem. 
GLAUCOMA AND DISABILITY: WHICH TASKS OF DAILY LIFE ARE AFFECTED?
Loss of visual function in glaucoma patients can affect walking, venturing out from home, reading, seeing at night, adjusting to different levels of illumination, judging distances, and seeing objects coming from the side [126, 127] . When glaucoma patients were asked to choose which activities were most important among hypothetical scenarios in which they had different levels of difficulty with different tasks, the greatest importance was given to tasks involving central and near vision (i.e., reading), with high scores also for mobility outside the home (i.e., driving and walking outside) [34, 50] . Problems like glare, bumping into objects, and household chores were considered minor [34] .
Difficulties with central and near vision tasks in general, and with reading specifically, are the most frequent complaint among people with eye disease. Near vision tasks such as reading are also the most valued visual function in those with glaucoma. While reading is clearly dependent on visual acuity, complaints of difficulty reading are commonplace and were noted in over 40% of the glaucoma patients [69] .
In the Salisbury Eye Evaluation Study (SES), subjects with bilateral glaucoma were almost five times more likely to report severe difficulty with near activities than those without glaucoma [128] . This confirms several clinic-based studies that report more vision-related difficulty with near vision tasks in the presence of glaucoma-related VF loss [69] . Data from SES, however, indicated significant discordance between measured reading speed and self-reported reading difficulty, particularly in people who read poorly. This disparity between measured reading speed and self-assessment highlights the need to use both questionnaire and direct testing methods to assess reading [129] .
Outdoor mobility is a priority for glaucoma patients [34, 50] , and driving is the primary means of transport among the elderly in the USA [130] . An analysis of patients enrolled in CIGTS showed that over 50% of driving patients reported at least ''some'' difficulties in tasks involving glare, while 22% reported at least ''some'' difficulties with tasks requiring peripheral vision. Drivers with moderate bilateral VF loss were more likely to report at least some difficulties with all the driving tasks investigated, compared to patients with mild or no bilateral VF defects.
The role of binocular VF in driving tasks was also investigated in other studies [64, 128, 131] .
The SEE study found a strong correlation between binocular VF and night driving tasks, also after adjusting for contrast sensitivity [128] .
The Los Angeles Latino Eye Study reported that bilateral moderate to severe VF loss had a great impact on driving tasks, while moderate to severe unilateral VF defects had less influence on driving capabilities [131] . The influence of the better and worse eye on driving in patients with glaucoma is not completely clear.
Perceived difficulty in driving tasks seems to increase with worsening VF damage in the better eye [30, 69, 131] .
Several studies have shown that glaucoma patients tend to modify their driving habits, as a result of perceiving difficulty with their vision [88, [132] [133] [134] [135] . Discontinuation of driving was significantly more frequent in patients with glaucoma in both eyes, but not in one eye, compared with healthy subjects [88] . Moreover, when compared with people without glaucoma, patients with glaucoma in both eyes more frequently reported vision-related discontinuation of driving at night, vision-related decreased driving frequency, and vision-related cessation of driving in unfamiliar areas.
CONCLUSION
Physicians are used to claiming the success of glaucoma management with parameters like IOP, visual fields, and damage progression. However, from the perspective of the patients, other concerns may be far more important [136] . The most frequent problems related to decreased vision were reading, walking on stairs, and recognizing people. Difficulties with these activities were more often reported by older patients than younger ones. This is not surprising and is probably more closely related to age itself than to glaucomatous damage.
Assessment of QoL with a questionnaire has several limitations. QoL assessment is subjective: patients with similar disability may rate their QoL differently. An inherent limitation of QoL assessment is that self-reported visual ability evaluated by any questionnaire can be impaired, at least to some extent, by other visual and systemic morbidity or psychosocial constraints.
Conceivably, even when perimetric indices such as MD are comparable, different determinants such as spatial distribution and depth of VF scotomas or speed of perimetric deterioration may affect patients with dissimilar lifestyles and expectations [76] .
Early detection of glaucoma is a vital objective in clinical management so that visual function and QoL are preserved [54, 55] .
Patients with early glaucoma often remain undiagnosed until progression to advanced stages. The present review underlines the importance of timely glaucoma diagnosis in preserving vision-related QoL. However, falsely diagnosing patients as having glaucoma can significantly reduce their QoL and well-being. 
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